Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 Net Margin % is 22.66% as of Dec. 2025, which is 6% above its 10-year median of 21.28. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 95.59% on this metric.
Net margin is calculated as Net Income divided by its Revenue. WuXi XDC Cayman's Net Income for the
six
months ended in Dec. 2025 was HK$812 Mil. WuXi XDC Cayman's Revenue for the
six
months ended in Dec. 2025 was HK$3,583 Mil. Therefore, WuXi XDC Cayman's net margin for the quarter that ended in Dec. 2025 was 22.66%.
The historical rank and industry rank for WuXi XDC Cayman's Net Margin % or its related term are showing as below:
HKSE:02268'
s Net Margin % Range Over the Past 10 Years
Min: 13.35 Med: 21.28 Max: 27.29
Current: 22.37
HKSE:02268's Net Margin % is ranked better than 95.59% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.75
vs HKSE:02268: 22.37
WuXi XDC Cayman (HKSE:02268) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
WuXi XDC Cayman Net Margin % Related Terms
WuXi XDC Cayman Net Margin % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: Net Margin % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Net Margin % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a Net Margin % of 22.66% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 21.28. Over the past decade, WuXi XDC Cayman's Net Margin % has ranged from 13.35 to 27.29. According to the industry distribution chart, WuXi XDC Cayman ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 4.4%.
Is WuXi XDC Cayman's Net Margin % too high?
WuXi XDC Cayman's current Net Margin % of 22.66% is near median its 10-year median of 21.28. Over the past 10 years, this metric has ranged from a low of 13.35 to a high of 27.29. Based on the distribution chart, WuXi XDC Cayman ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #9 out of 204 companies for Net Margin %. This places WuXi XDC Cayman in the top 4% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own Net Margin % has ranged from 13.35 to 27.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current Net Margin % is 22.66%, which is near median its own 10-year median of 21.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current Net Margin % of 22.66%. The current Net Margin % is 22.66%, which is near median its 10-year median of 21.28. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current Net Margin % is 22.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
